netFormulary NHS
Birmingham, Sandwell, Solihull and environs APC Formulary
Maintained by Midlands and Lancashire Commissioning Support Unit
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund list

 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
08.01.05  Expand sub section  Brentuximab vedotin
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide
08.01.05  Expand sub section  Ipilimumab
08.01.05  Expand sub section  Mitotane
08.01.05  Expand sub section  Panitumumab to top
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine
08.01.05  Expand sub section  Protein kinase inhibitors to top
Afatinib (Giotrif®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
  • In line with NICE 
  • Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
       
    Alectinib
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    NHS England

    In line with NICE

     
    Link  Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
       
    Cabozantinib (Cabometyx®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    In line with NICE 
    Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
    Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
       
    Crizotinib (Xalkori®)
    View adult BNF View SPC online View childrens BNF
    Restricted Drug Restricted
    Red
    High Cost Medicine
  • Hospital only- NHSE commissioned
  • In line with NICE 
  • Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
    Link  NICE TA406:Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
    Link  NICE TA 529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
       
    Dasatinib (Sprycel®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    In line with NICE 
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
    Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
       
    Everolimus (Afinitor®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    In line with NICE
    Hospital only-NHSE commissioned 
    Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
    Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
    Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
       
    Everolimus (Votubia®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
       
    Gefitinib (Iressa®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
    Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
       
    Cytotoxic Drug Imatinib (Glivec®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    in line with NICE 
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
    Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
    Link  NICE TA326: Gastrointestinal stromal tumours - imatinib (adjuvant): guidance
    Link  NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib. NOT RECOMMENDED
    Link  NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
       
    Lapatinib (Tyverb®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
    Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
       
    Nilotinib (Tasigna®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    In line with NICE 
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
    Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
       
    Pazopanib (Votrient®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
    Link  NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
       
    Ponatinib (Iclusig®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    In line with NICE 
    Link  NICE TA451:Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
       
    Regorafenib (Stivarga® )
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
  • In line with NICE
  • NHS E commissioned 
  • Link  NICE TA 555:Regorafenib for previously treated advanced hepatocellular carcinoma
    Link  NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
       
    Sorafenib (Nexavar®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
     
    Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
       
    Sunitinib (Sutent®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
     
    Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
    Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
    Link  NICE TA178: Renal cell carcinoma
    Link  NICE TA169: Renal cell carcinoma - sunitinib
       
    Cytotoxic Drug Temsirolimus (Torisel®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
     
    Link  NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
    Link  NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
       
    Tivozanib (Fotivda®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    NHS England

    In line with NICE

     
    Link  NICE TA512:Tivozanib for treating advanced renal cell carcinoma
       
    Vemurafenib (Zelboraf®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    In line with NICE 
    Link  NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
    Link  NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
       
    08.01.05  Expand sub section  Taxanes
    08.01.05  Expand sub section  Topoisomerase I inhibitors
    08.01.05  Expand sub section  Trabectedin
    08.01.05  Expand sub section  Trastuzumab
    08.01.05  Expand sub section  Tretinoin to top
    08.01.05  Expand sub section  Vismodegib
     ....
     Non Formulary Items
    Cytotoxic Drug  Vandetanib  (Caprelsa®)

    View adult BNF View SPC online View childrens BNF
    Non Formulary
    Link  NICE TA550: Vandetanib for treating medullary thyroid cancer
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to children's BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Prescribing in children

    The APC notes that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications (‘off-label’ use) is often necessary in paediatric practice.

    The APC advises GPs to consider specialist prescribing recommendations for Green and Amber medicines that are not subject to ESCAs or RICaDs in combination with the information provided in the BNFC which goes beyond that of marketing authorisations. The BNFC has been designed for rapid reference and the information presented has been carefully selected to aid decisions on prescribing.

      

    Green

    Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications.  

    Amber

    Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate, or initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.

    Some amber medicines require agreement with the local (internal) medicines committee prior to initiation; others may require a framework to support safe transfer and maintenance of care such as a RICaD or ESCA. The Formulary will be annotated to reflect these requirements.   

    Red

    Medicines for initiation and maintenance prescribing by Specialists only  

    Black

    Non-formulary medicines- medicines not recommended for routine primary care prescribing.  

    Grey

    Positive NICE TA and /or awaiting local clarification on place in therapy ; Please contact your Medicines Optimisation team for more information.  

    netFormulary